# LUMYKRAS™ (sotorasib) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/sotorasib

> LUMYKRAS™ (sotorasib), sponsored by AMGEN INC (AMGN), received a complete response letter from the FDA; the decision is dated Mar 2023.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | LUMYKRAS™ (sotorasib) |
| Codes | AMG-510 |
| Sponsor | AMGEN INC (AMGN) https://sec-api.dev/companies/amgn/catalysts |
| Indications | [Advanced Solid Tumors](https://sec-api.dev/indications/advanced-solid-tumors), [Non-small Cell Lung Cancer](https://sec-api.dev/indications/non-small-cell-lung-cancer), [Colorectal Cancer (CRC)](https://sec-api.dev/indications/colorectal-cancer-crc), [Non-Small Cell Lung Cancer (NSCLC)](https://sec-api.dev/indications/non-small-cell-lung-cancer-nsclc), [Metastatic Colorectal Cancer](https://sec-api.dev/indications/metastatic-colorectal-cancer) |
| Modality | small_molecule |
| FDA designations | accelerated, priority review |

## Timeline

### May 28, 2021: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA214665 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20210528, review_priority PRIORITY; sponsor_name AMGEN INC; product LUMAKRAS (SOTORASIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214665%22

### Mar 2023: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: month. Stage: 3.
- First seen 2025-02-14, last confirmed 2026-11-04.
- SEC Form 10-Q (accession 0000318154-26-000155): "Following our submission of the LUMAKRAS/LUMYKRAS CodeBreaK 200 Phase 3 confirmatory data in March 2023 to the FDA and EMA, we received a Complete Response Letter from the FDA and a new postmarketing requirement for an additional confirmatory study to support full approval." https://www.sec.gov/Archives/edgar/data/318154/000031815426000155/amgn-20260930.htm
- SEC Form 10-Q (accession 0000318154-26-000126): "Following our submission of the LUMAKRAS/LUMYKRAS CodeBreaK 200 Phase 3 confirmatory data in March 2023 to the FDA and EMA, we received a Complete Response Letter from the FDA and a new postmarketing requirement for an additional confirmatory study to support full approval." https://www.sec.gov/Archives/edgar/data/318154/000031815426000126/amgn-20260630.htm
- SEC Form 10-Q (accession 0000318154-26-000057): "Following our submission of the LUMAKRAS/LUMYKRAS CodeBreaK 200 Phase 3 confirmatory data in March 2023 to the FDA and EMA, we received a Complete Response Letter from the FDA and a new postmarketing requirement for an additional confirmatory study to support full approval." https://www.sec.gov/Archives/edgar/data/318154/000031815426000057/amgn-20260331.htm
- SEC Form 10-K (accession 0000318154-26-000010): "Following our submission of the LUMAKRAS/LUMYKRAS CodeBreaK 200 Phase 3 confirmatory data in March 2023 to the FDA and EMA, we received a Complete Response Letter from the FDA and a new post-marketing requirement for an additional confirmatory study to support full approval." https://www.sec.gov/Archives/edgar/data/318154/000031815426000010/amgn-20251231.htm
- SEC Form 10-Q (accession 0000318154-25-000020): "Following our submission of the LUMAKRAS/LUMYKRAS CodeBreaK 200 Phase 3 confirmatory data in March 2023 to the FDA and EMA, we received a Complete Response Letter from the FDA and a new post-marketing requirement for an additional confirmatory study to support full approval." https://www.sec.gov/Archives/edgar/data/318154/000031815425000020/amgn-20250331.htm
- SEC Form 10-K (accession 0000318154-25-000010): "Following our submission of the LUMAKRAS/LUMYKRAS CodeBreaK 200 Phase 3 confirmatory data in March 2023 to the FDA and EMA, we received a Complete Response Letter from the FDA and a new post-marketing requirement for an additional confirmatory study to support full approval." https://www.sec.gov/Archives/edgar/data/318154/000031815425000010/amgn-20241231.htm

### October 5, 2023: FDA advisory committee meeting

- Status: completed, negative. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA advisory committee calendar: "The Committee will discuss supplemental new drug application (sNDA) 214665/S-005, for LUMAKRAS (sotorasib) tablets, submitted by Amgen Inc., for the proposed treatment of adult patients with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer, as determined by an FDA approved test, who have received at least one prior systemic therapy." https://www.fda.gov/advisory-committees/advisory-committee-calendar/october-5-2023-meeting-oncologic-drugs-advisory-committee-meeting-announcement-10052023
- FDA advisory committee calendar: "VOTE: Can the primary endpoint, progression-free survival (PFS) per blinded independent central review (BICR), be reliably interpreted in CodeBreak200? Vote Result: Yes: 2 No: 10 Abstain: 0" https://www.fda.gov/media/174559/download

### January 16, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA214665 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20250116, review_priority PRIORITY; sponsor_name AMGEN INC; product LUMAKRAS (SOTORASIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214665%22

### May 28, 2025: primary completion

- Status: withdrawn. Date confidence: exact. Stage: 2. Indication: Non-small Cell Lung Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04933695 (A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-05-28 (ACTUAL); Lead Sponsor Amgen; Results First Posted 2026-07-13." https://clinicaltrials.gov/study/NCT04933695

### July 16, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Colorectal Cancer (CRC).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05198934 (Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-16 (ACTUAL); Lead Sponsor Amgen; Results First Posted 2026-07-22." https://clinicaltrials.gov/study/NCT05198934

### July 22, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 3. Indication: Colorectal Cancer (CRC).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05198934 (Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-16 (ACTUAL); Lead Sponsor Amgen; Results First Posted 2026-07-22." https://clinicaltrials.gov/study/NCT05198934?tab=results

### Jun to Sep 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Non-Small Cell Lung Cancer (NSCLC).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05920356 (A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor Amgen." https://clinicaltrials.gov/study/NCT05920356

### June 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Non-Small Cell Lung Cancer (NSCLC).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05920356 (A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor Amgen." https://clinicaltrials.gov/study/NCT05920356

### July 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Advanced Solid Tumors.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07172919 (A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-07-01 (ESTIMATED); Lead Sponsor Amgen." https://clinicaltrials.gov/study/NCT07172919

### Jul to Oct 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Advanced Solid Tumors.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07172919 (A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-07-01 (ESTIMATED); Lead Sponsor Amgen." https://clinicaltrials.gov/study/NCT07172919

### Sep to Dec 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Metastatic Colorectal Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06252649 (Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-25 (ESTIMATED); Lead Sponsor Amgen." https://clinicaltrials.gov/study/NCT06252649

### September 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Metastatic Colorectal Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06252649 (Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-25 (ESTIMATED); Lead Sponsor Amgen." https://clinicaltrials.gov/study/NCT06252649

## Same indication

- [Botvymo® (botensilimab)](https://sec-api.dev/pdufa/botensilimab) (AGEN)
- [Calderasib](https://sec-api.dev/pdufa/calderasib) (MRK)
- [CTX-009](https://sec-api.dev/pdufa/ctx-009) (CMPX)
- [Datopotamab deruxtecan](https://sec-api.dev/pdufa/datopotamab-deruxtecan) (AZN)
- [Encorafenib](https://sec-api.dev/pdufa/encorafenib) (PFE)
- [Fianlimab](https://sec-api.dev/pdufa/fianlimab) (REGN)
- [LBL-007](https://sec-api.dev/pdufa/lbl-007) (ONC)
- [Opdivo® (nivolumab)](https://sec-api.dev/pdufa/nivolumab) (BMY)
- [Onvansertib](https://sec-api.dev/pdufa/onvansertib) (CRDF)
- [Tagrisso® (osimertinib)](https://sec-api.dev/pdufa/osimertinib) (AZN)
- [Pumitamig](https://sec-api.dev/pdufa/pumitamig) (BMY)
- [Rp1](https://sec-api.dev/pdufa/rp1) (REPL)
- [Sacituzumab govitecan-hziy (sg)](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy-sg) (GILD)
- [ORPATHYS® (savolitinib)](https://sec-api.dev/pdufa/savolitinib) (HCM)
- [Telisotuzumab adizutecan](https://sec-api.dev/pdufa/telisotuzumab-adizutecan) (ABBV)
- [Telisotuzumab vedotin](https://sec-api.dev/pdufa/telisotuzumab-vedotin) (ABBV)
- [TEVIMBRA® (tislelizumab)](https://sec-api.dev/pdufa/tislelizumab) (ONC)
- [Volrustomig](https://sec-api.dev/pdufa/volrustomig) (AZN)
- [YuTuo (zimberelimab)](https://sec-api.dev/pdufa/zimberelimab) (GILD)

Calendar months: [June 2027](https://sec-api.dev/fda-calendar/2027-06), [July 2028](https://sec-api.dev/fda-calendar/2028-07), [September 2028](https://sec-api.dev/fda-calendar/2028-09)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/sotorasib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "LUMYKRAS™ (sotorasib) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/sotorasib

```bibtex
@misc{secapidev_pdufa_sotorasib_20261116,
  title        = {LUMYKRAS™ (sotorasib) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/sotorasib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_sotorasib_20261116","title":"LUMYKRAS™ (sotorasib) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/sotorasib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
